On April 12, 2021 Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immunooncology company developing innovative drug candidates for the prevention and treatment of cancer, reported that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm’s length parties (Press release, Helix BioPharma, APR 12, 2021, View Source [SID1234577903]). The Warrants were issued pursuant to a private placement of the Company completed on April 27, 2016 and represent approximately 2.0% of the Company’s issued and outstanding common shares.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each Warrant currently entitles the holder to purchase one common share of the Company at an exercise price of $1.98 at any time until April 27, 2021. Subject to TSX approval, the expiry date of the Warrants will be extended by two years to April 26, 2023. The exercise price of the Warrants will remain unchanged at $1.98. If approved by the TSX, the effective date of the amendment will be April 27, 2021.